Andina Acquisition Corp. III ANDA
9.20 0.00 (+0.00%)
At closeJul 21, 2021, 12:00 AM EDT
8.90 Day range 9.92
52-week range unavailable
- Market cap
- 335.92M
- Shares out
- 4.42M
- Volume
- 314.27K
- Open
- 9.00
- Previous close
- 9.20
- Day's range
- 8.90 – 9.92
- Beta
- 0.00
No chart data for this range yet.
Key statistics
- Enterprise value
- 34.83M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 368.53K
- Total cash
- 77.20K
- Total debt
- 0
- Return on equity
- -168.12%
- Short % of float
- 12.01%
- 50-day average
- 10.18
- 200-day average
- 10.54
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 8, 2021 | Northland Capital Markets | init | — | Outperform |
About Andina Acquisition Corp. III
Andina Acquisition Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to engage in the business of manufacturing, marketing, and selling healthy snacks products. The company was incorporated in 2016 and is based in Bogotá, Colombia.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- Colombia
News
Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval 
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection 
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine 
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation 
Supernus Announces Paragraph IV ANDA Filings for Qelbree® 
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 
Hikma acquires Novugen's FDA-approved ANDA for trametinib
Your note
Sign in to keep a note on ANDA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cowen and Company, LLC | 9.28% | 409,967 | 4.21M | Mar 30, 2021 |
| K2 Principal Fund, L.P. | 4.05% | 178,883 | 1.84M | Mar 30, 2021 |
| Tenor Capital Management Co., L.p. | 3.55% | 156,979 | 1.61M | Mar 30, 2021 |
| Cooper Creek Partners Management LLC | 2.78% | 122,914 | 1.26M | Mar 30, 2021 |
| AWM Investment Company, Inc. | 2.26% | 100,000 | 1.03M | Mar 30, 2021 |
| Ophir Asset Management Pty Ltd | 1.93% | 85,217 | 875.18K | Mar 30, 2021 |